Lung Cancer

This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation.
Savolitinib had promising antitumor activity in patients with METex14+ NSCLC and showed acceptable tolerability.
First-line treatment with osimertinib in patients with EGFR-mutated is associated with longer overall survival compared with other drugs in its class.
Researchers presented updated 5-year progression-free survival and overall survival data from a clinical trial evaluating the efficacy and safety of alectinib versus crizotinib in previously untreated patients with ALK-positive NSCLC.
Treatment with combination apatinib and gefitinib is associated with improved progression-free survival compared with treatment with gefitinib alone in patients with NSCLC and EGFR mutations.
A phase 1 clinical trial of the HER3-directed antibody–drug conjugate patritumab deruxtecan shows potential for treating patients with EGFR-mutated NSCLC.
Study results show no increase in progression-free survival with combination treatment of osimertinib and bevacizumab compared with osimertinib alone for patients with advanced lung adenocarcinoma and an EGFR T790M mutation.
Patients treated with afatinib for EGFR-mutated (EGFRm) non–small-cell lung cancer (NSCLC) often require treatment modifications because of drug toxicities. This study aimed to evaluate the safety and efficacy of a lower dosage of afatinib in patients with EGFRm NSCLC.
Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC.
Dr David Spigel reviews 5 practice-changing presentations from 2020 on the treatment of metastatic NSCLC using immunotherapy alone or in combination with chemotherapy or targeted agents.
Page 3 of 11
Results 21 - 30 of 109